SIRIO Pharma, a global contract development and manufacturing organisation (CDMO), has announced a €16 million investment in a new packaging facility at its Pritzwalk campus near Berlin, Germany. This expansion brings the company’s total investment at the site to €19
SIRIO Pharma, a global Contract Development and Manufacturing Organisation (CDMO), has announced a €16 million investment in a new packaging facility at its campus in Pritzwalk, near Berlin. This investment increases the total expenditure at the site to €19 million
Lonza has completed the expansion of its Drug Product Services (DPS) site in Basel, Switzerland, adding a new facility for quality control (QC) and bioanalytics. The 6000m² addition will support both clinical and commercial projects, allowing the company to increase
Cryoport, Inc. has announced a new strategic partnership with VGXI, Inc., aimed at bolstering supply chain services for biopharmaceutical companies developing cell and gene therapies, as well as mRNA-based treatments. The collaboration will leverage Cryoport’s biostorage and bioservices to manage
VGXI, Inc., a contract developer and manufacturer of nucleic acid biopharmaceuticals has announced a strategic partnership with Cryoport, Inc., a global provider in life sciences supply chain solutions. The collaboration aims to support biopharmaceutical companies in developing advanced therapies, including
LGM Pharma has announced the expansion of its Analytical Testing Services with the introduction of endotoxin and rapid sterility testing at its Irvine, California facility. This move responds to growing demand for reliable and fast testing for sterile compounds, offering
“Customer centricity is something that is lacking in our industry, and we knew we could do it differently,” says Adragos Pharma CCO Henny Zijlstra, discussing the company’s mission to transform pharmaceutical contract manufacturing. Henny Zijlstra serves as Chief Commercial Officer
“In underserved markets, there’s always a challenge of reaching patients due to political and economic pressures. Through smart packaging, logistics, and distribution, we’re committed to providing healthcare solutions across our network of more than 100 distributors,” says Samir El Nasharty,
“The industry is back, and we’re uniquely positioned to provide end-to-end services, including clinical trials. That’s what we mean by CDMO plus CRO – it’s a complete 360-degree set of operations,” says Dr. Anil Kane, Executive Director and Global Head
Lundbeck has signed an agreement to acquire Longboard Pharmaceuticals for $2.6 billion, boosting its capabilities in the treatment of neuro-rare conditions. The acquisition includes Longboard’s lead drug candidate, bexicaserin, which is under evaluation in a Phase III clinical trial targeting
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
